Advertisement

Topics

J&J optimistic in spite of biosimilar threat

10:48 EDT 18 Oct 2016 | BioPharmaDive

Bracing for competition to Remicade, J&J lays out the strategic reasons it can retain market share. 

Original Article: J&J optimistic in spite of biosimilar threat

NEXT ARTICLE

More From BioPortfolio on "J&J optimistic in spite of biosimilar threat"

Quick Search
Advertisement
 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...